HERON THERAPEUTICS, INC.

Analyst Reco. Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
2.55 ^USD	+8.97%		0.00%	+50.00%

Apr. 23	Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target	MT
Mar. 21	Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target	Apr. 23	MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $4, Keeps Buy Rating	Mar. 13	MT
Needham Trims Price Target on Heron Therapeutics to $4 From $5, Keeps Buy Rating	Nov. 15	MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $6, Maintains Buy Rating	23-07-25	MT
Needham Adjusts Heron Therapeutics' Price Target to $6 From $7, Keeps Buy Rating	23-05-12	MT
Needham Adjusts Price Target on Heron Therapeutics to $6 From $7, Maintains Buy Rating	23-05-12	MT
Evercore ISI Adjusts Price Target on Heron Therapeutics to $10 From $15, Maintains Outperform Rating	23-03-24	MT
Needham Adjusts Price Target on Heron Therapeutics to $7 From $8, Keeps Buy Rating	23-03-24	MT
Needham Trims Price Target on Heron Therapeutics to $8 From $10, Maintains Buy Rating	22-11-09	MT
Cantor Fitzgerald Adjusts Price Target for Heron Therapeutics to $12 From $20, Maintains Overweight Rating	22-05-10	MT
Needham Adjusts Heron Therapeutics' Price Target to $14 from $16, Keeps Buy Rating	22-05-10	MT
Cowen & Co Adjusts Heron Therapeutics Price Target to $13 From $31, Maintains Outperform Rating	22-03-01	MT
Needham & Co Adjusts Heron Therapeutics Price Target to $16 From $24, Maintains Buy Rating	22-03-01	MT
HERON THERAPEUTICS : Stifel Adjusts Heron Therapeutics' Price Target to $25 from $20, Keeps Buy Rating	21-01-05	MT
HERON THERAPEUTICS : SVB Leerink Adjusts Heron Therapeutics' Price Target to $24 From $21, Keeps at Outperform	20-12-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer